• 繁

    • -+ 0.00%
    -+ 0.00%
    -+ 0.00%

    BeOne Medicines (ONC): Reassessing Valuation After FDA Fast Track and Priority Review Boost Oncology Pipeline Momentum

    Simply Wall St·12/20/2025 01:23:57
    語音播報

    BeOne Medicines (ONC) is back in focus after the FDA granted Fast Track Designation to its liver cancer bispecific BGB-B2033 and accepted sonrotoclax for Priority Review, underscoring real momentum across its oncology pipeline.

    See our latest analysis for BeOne Medicines.

    Those back to back FDA milestones have arrived after a choppy few weeks, with a 30 day share price return of minus 10.7 percent but a powerful year to date share price gain of 71.8 percent. This suggests underlying momentum is still building as investors recalibrate the company’s risk reward story.

    If this kind of oncology momentum has your attention, it could be worth scanning other potential winners across healthcare stocks to see what else fits your watchlist.

    With BeOne Medicines trading around 27 percent below consensus targets despite nearly 72 percent year to date gains, is the market still underestimating its oncology pipeline, or already pricing in the next leg of growth?

    Most Popular Narrative Narrative: 21.3% Undervalued

    With BeOne Medicines closing at 316.05 dollars versus a narrative fair value of about 402 dollars, the valuation story leans firmly toward upside driven by its growth agenda.

    BeOne's strong revenue growth (41 percent year on year in Q2, updated full year guidance of 5 billion dollars to 5.3 billion dollars) is underpinned by rapid demand expansion for differentiated, best in class oncology therapies like BRUKINSA, supported by a growing, aging population and increased global healthcare spending, both of which point to a sustainably expanding addressable market and future revenue growth.

    Read the complete narrative.

    Want to see what kind of future revenue curve justifies that uplift, and how profit margins and valuation multiples are modeled to stretch far beyond today? Dive into the narrative drivers behind this target.

    Result: Fair Value of $401.52 (UNDERVALUED)

    Have a read of the narrative in full and understand what's behind the forecasts.

    However, analysts warn that heavy reliance on BRUKINSA and intensifying BTK competition could derail growth expectations if trial data or pricing dynamics disappoint.

    Find out about the key risks to this BeOne Medicines narrative.

    Build Your Own BeOne Medicines Narrative

    If you see the story unfolding differently, or want to test your own assumptions against the numbers, you can build a personalized view in under three minutes: Do it your way.

    A great starting point for your BeOne Medicines research is our analysis highlighting 5 key rewards and 1 important warning sign that could impact your investment decision.

    Looking for more investment ideas?

    Do not stop at a single opportunity; put Simply Wall Street's screener to work so you can quickly uncover fresh stocks that match your strategy.

    This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.